News >

Nivolumab Shows Promise in Mesothelioma

Virginia Powers, PhD
Published: Wednesday, Dec 14, 2016

Paul Baas, MD, PhD

Paul Baas, MD, PhD

Treatment with the PD-1 inhibitor nivolumab (Opdivo) showed promising results in patients with recurrent malignant pleural mesothelioma (MPM), according to findings from the phase II Nivo-Mes trial presented at the 17th World Lung Cancer Conference in Vienna.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication